12:00 AM
 | 
Sep 16, 2002
 |  BioCentury  |  Product Development

Avastin: Quick hit didn’t pay off

Genentech Inc. took a gamble with its Avastin anti-VEGF antibody in metastatic breast cancer and it failed to pay off last week, as the compound failed to show progression-free survival in a Phase III trial. But by taking on a population with more advanced disease and selecting a more difficult endpoint, DNA had taken a chance on getting to market faster than it could in its lead indication of colorectal cancer, where the company is running more robust trials.

Thus DNA holds out optimism that the breast cancer results don’t affect Avastin’s chances in colorectal...

Read the full 464 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >